Skip to main content
OpenTrials
Not yet recruiting

NCT Number: NCT07824557

StressModex for Post-Traumatic Neck Pain

Post-traumatic neck pain is a common consequence of traffic-related and other accidental injuries. While many individuals recover, a subgroup develops persistent pain, disability, and psychological distress. Building on previous adaptation and feasibility work, this randomised pilot trial will assess the feasibility of conducting a future definitive randomised controlled trial comparing StressModex plus treatment as usual (TAU) with TAU alone in individuals at risk of persistent post-traumatic neck pain.

The primary feasibility objectives are to assess recruitment using a revised multi-source recruitment strategy and participant retention and remote outcome data collection. Secondary feasibility objectives are to assess the feasibility and acceptability of randomisation, characterise TAU and concurrent healthcare use, and estimate parameters relevant to the sample size calculation for a future definitive RCT. Intervention fidelity, adherence, acceptability, safety, and practical aspects of intervention delivery will additionally be monitored. The pilot trial is not designed or powered to evaluate the effectiveness of StressModex.

Not yet recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital of Southern Jutland, Aabenraa, Denmark

Loading trial locations.

About this study

Persistent post-traumatic neck pain is associated with substantial disability, reduced quality of life, psychological distress, and societal costs. Previous research has identified psychological stress responses and hyperarousal symptoms following trauma as important predictors of poor recovery. Interventions combining physical rehabilitation with psychological approaches may therefore be relevant for individuals at increased risk of persistent post-traumatic neck pain.

StressModex integrates guideline-based physiotherapy with Stress Inoculation Training (SIT) and has previously been adapted to a Danish healthcare context. A preceding feasibility study evaluated the acceptability and feasibility of the adapted intervention and study procedures. While the intervention was found to be acceptable and deliverable, recruitment and retention were identified as important remaining uncertainties. Based on these findings, the recruitment strategy and trial procedures have subsequently been revised.

Building on this previous adaptation and feasibility work, the present study is designed as a two-arm randomised pilot trial. The aim is to assess the feasibility of conducting a future definitive RCT evaluating StressModex plus treatment as usual (TAU) compared with TAU alone and to generate information required to refine the design of the definitive trial.

Adults with post-traumatic neck pain of less than six months' duration who demonstrate both moderate neck-related disability and hyperarousal symptoms will be recruited through a revised multi-source recruitment strategy, including emergency departments, hospital records, healthcare providers and settings, health insurance providers, and public advertisements including social media. Following informed consent and completion of baseline questionnaires, participants will be randomised in a 1:1 ratio to either StressModex plus TAU or TAU alone.

StressModex consists of 10 physiotherapy sessions delivered over six weeks and combines individually tailored, guideline-based physiotherapy with SIT. SIT is integrated into six sessions and focuses on understanding and managing stress responses, developing coping and stress-management skills, and applying these skills in relevant situations. Participants in both trial arms remain free to seek healthcare according to usual Danish practice.

The primary objectives are to assess whether the revised multi-source recruitment strategy can identify and include eligible participants at a rate sufficient to support a future definitive RCT and to assess participant retention and the feasibility and completeness of remote outcome data collection through 6 months. Secondary objectives are to assess the feasibility and acceptability of randomisation, characterise TAU, and concurrent healthcare use and potential overlap with the StressModex intervention, and estimate parameters relevant to the sample size calculation for a future definitive RCT. Intervention fidelity, adherence, acceptability, safety, and practical aspects of intervention delivery will additionally be monitored.

Clinical outcomes, including neck-related disability, pain, psychological symptoms, quality of life, and physical activity, will be collected primarily to assess the feasibility and completeness of outcome data collection and, where relevant, to estimate parameters required to inform the design of a future definitive RCT. Register-based data on healthcare utilisation, medication use, and work participation will also be collected to inform procedures and the design of a future health-economic evaluation. The pilot trial is not powered to evaluate clinical effectiveness, and no confirmatory between-group effectiveness testing is planned. Participants will be followed for six months after randomisation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Post-traumatic neck pain with symptom duration of less than 6 months
  • Moderate neck-related disability, defined as Neck Disability Index (NDI) score ≥32%
  • Hyperarousal symptoms defined as a score of ≥3 on the hyperarousal subscale of the Posttraumatic Diagnostic Scale (PDS)
  • Able to read, understand, and communicate in Danish

Exclusion criteria

  • Known or suspected spinal pathology, including confirmed fracture or vertebral displacement related to the injury
  • Severe pre-existing pain condition judged to interfere with participation in the intervention, such as disc herniation, fractures, or recent major surgery
  • Known severe psychiatric disorder, including schizophrenia spectrum disorder or bipolar disorder, if the condition is currently considered unstable, insufficiently treated, or likely to affect the participant's ability to provide informed consent or participate meaningfully in the study
  • Known active misuse of alcohol, illicit drugs, anxiolytic medication, or opioids
  • Progressive neurological or rheumatological disorder causing substantial functional limitations and expected to interfere with participation in the intervention or assessment of treatment effect
  • Severe traumatic brain injury

Treatment and study plan

StressModex plus Treatment as Usual

Behavioral

StressModex is a physiotherapist-delivered intervention combining guideline-based exercise therapy with stress inoculation training. Participants receive 10 treatment sessions over six weeks. Exercise components target neck mobility, strength, endurance, and sensorimotor function. Stress inoculation training components are integrated into six sessions and focus on stress education, relaxation strategies, coping skills, and self-management of stress-related symptoms following trauma.

Primary outcomes

  1. Recruitment rate

    Time frame: Throughout the active recruitment period, up to 10 months

    Recruitment rate will be assessed as the number of participants randomised per month during the active recruitment period. Recruitment will be evaluated against prespecified progression criteria: ≥5 participants per month (go), 3 to <5 participants per month (amend), and <3 participants per month (stop/reconsider).

  2. Participant retention at 6-month follow-up

    Time frame: 6 months after randomisation

    Retention will be assessed as the proportion of randomised participants retained at the 6-month follow-up. Retention will be evaluated against prespecified progression criteria: ≥75% retention (go), 50 to <75% retention (amend), and <50% retention (stop/reconsider).

Secondary outcomes

  1. Participant retention at 6-week and 3-month follow-up

    Time frame: 6 weeks and 3 months after randomisation

    Retention will be assessed as the proportion of randomised participants retained at each follow-up time point. Reasons for withdrawal or loss to follow-up will be recorded where available.

  2. Completeness of remotely collected outcome data

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Completeness of remotely collected outcome data will be assessed at each time point. The proportion of participants providing complete NDI data will be reported separately, as NDI is the proposed primary clinical outcome for a future definitive RCT. NDI data completeness of ≥80% will be considered acceptable, 70 to <80% will indicate that modifications to data collection procedures should be considered, and <70% will indicate substantial feasibility concerns. Completeness of the remaining questionnaire battery will also be described.

  3. Acceptance of randomisation

    Time frame: At enrolment, prior to randomisation

    Acceptance of randomisation will be assessed as the proportion of eligible individuals invited to participate in the trial who provide informed consent to participation and randomisation. Reasons for declining participation will be recorded where available. Acceptance of ≥80% will be considered acceptable, 60 to <80% will indicate that modifications to recruitment or trial information procedures should be considered, and <60% will indicate substantial concerns regarding the feasibility of the randomised design

  4. Withdrawal following treatment allocation

    Time frame: From randomisation to 6-month follow-up

    The proportion of randomised participants who withdraw from the study following treatment allocation will be assessed by trial arm. Reasons for withdrawal, including reasons related to treatment allocation, will be recorded where available.

  5. Treatment as usual and concurrent healthcare use

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Healthcare use will be assessed by participant report, including the type and extent of healthcare received and medication use. Data will be used to characterise treatment as usual and concurrent healthcare use in both trial arms and to identify potential overlap between usual care and components of StressModex.

  6. Intervention fidelity

    Time frame: Throughout the 6-week intervention period

    Intervention fidelity will be assessed using therapist-completed standardised checklists after each treatment session, documenting delivery of the core StressModex intervention components. Fidelity will be summarised as the proportion of planned core intervention components delivered as intended.

  7. Intervention adherence and completion

    Time frame: Throughout the 6-week intervention period

    Intervention adherence will be assessed based on initiation and completion of the intervention, attendance at scheduled treatment sessions, and participant-reported adherence to prescribed home exercises. Treatment attendance will be summarised as the proportion of scheduled sessions attended.

  8. Acceptability of the StressModex intervention

    Time frame: 6 weeks, 3 months and 6 months after randomisation

    Acceptability of the StressModex intervention will be explored among participants allocated to the intervention through semi-structured interviews. Interviews will address participants' experiences of the intervention, including perceived relevance, burden, barriers and facilitators to participation, application in everyday life, and practical aspects of treatment delivery, as well as their general reflections also on symptom development.

  9. Clinician perspectives on intervention delivery and implementation

    Time frame: Following intervention delivery

    Clinicians delivering StressModex will participate in semi-structured interviews exploring experiences of intervention delivery, implementation, barriers, facilitators, and practical considerations relevant to a future definitive RCT.

  10. Variability of Neck Disability Index score to inform a future definitive RCT

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Neck-related disability will be measured using the Neck Disability Index (NDI). The variability of NDI scores will be estimated to provide trial-specific information for refinement of the sample size calculation for a future definitive RCT. Estimates will be interpreted alongside relevant external evidence and will not be used for confirmatory effectiveness testing

Other outcomes

  1. Pain intensity

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Pain intensity during the previous 24 hours will be measured using the Numeric Rating Scale (NRS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores indicate greater pain intensity and therefore a worse outcome.

  2. Post-traumatic stress symptoms

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Post-traumatic stress symptoms will be assessed using the Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5). The total score ranges from 0 to 80, with higher scores indicating greater post-traumatic stress symptom severity and therefore a worse outcome.

  3. Hyperarousal symptoms

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Hyperarousal symptoms will be assessed using the hyperarousal subscale of the Posttraumatic Diagnostic Scale (PDS). The subscale score ranges from 0 to 15, with higher scores indicating greater hyperarousal symptom severity.

  4. Depression, anxiety, and stress symptoms

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Symptoms of depression, anxiety, and stress will be assessed using the 21-item Depression Anxiety Stress Scales (DASS-21). The instrument comprises three subscales: depression, anxiety, and stress. Each subscale score ranges from 0 to 42, with higher scores indicating greater symptom severity

  5. Pain catastrophizing

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Pain catastrophizing will be assessed using the Pain Catastrophizing Scale (PCS). The total score ranges from 0 to 52, with higher scores indicating greater pain catastrophizing

  6. Pain self-efficacy

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Pain self-efficacy will be assessed using the Pain Self-Efficacy Questionnaire (PSEQ). The total score ranges from 0 to 60, with higher scores indicating greater confidence in performing activities despite pain

  7. Health-related quality of life

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). Health states will be converted to an EQ-5D-5L index value using the Danish value set, with higher values indicating better health-related quality of life.

  8. Health related quality of life - EQ VAS

    Time frame: Baseline, 6 weeks, 3 months and 6 months

    The EQ Visual Analogue Scale (EQ VAS) ranges from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state; higher scores indicate a better outcome

  9. Sleepiness

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Subjective sleepiness will be assessed using the Karolinska Sleepiness Scale (KSS). The scale ranges from 1 to 9, with higher scores indicating greater subjective sleepiness

  10. Expected recovery

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Participants' expectations of recovery will be assessed using an 11-point numerical rating scale ranging from 0% to 100%, with higher scores indicating greater expected recovery.

  11. Pain characteristics

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Pain characteristics will be assessed using the Short-Form McGill Pain Questionnaire (SF-MPQ), which assesses sensory and affective qualities of pain and pain intensity. Higher scores indicate greater pain severity.

  12. Treatment credibility and expectancy

    Time frame: Baseline

    Treatment credibility and expectancy will be assessed using the Credibility/Expectancy Questionnaire (CEQ). The questionnaire comprises two subscales: treatment credibility and treatment expectancy. Credibility is assessed using three items rated from 1 to 9, while expectancy is assessed using two items rated from 1 to 9 and one item rated from 0% to 100%. Higher scores indicate greater treatment credibility and more positive expectations of treatment outcome.

  13. Physical activity

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Self-reported physical activity will be assessed using a standardised physical activity questionnaire

  14. Global Rating of Change

    Time frame: 6 weeks, 3 months, and 6 months

    Participants' perceived overall change in their neck condition will be assessed using the Global Rating of Change (GROC) scale. Scores range from -7 ("a very great deal worse") to +7 ("a very great deal better"), with 0 indicating no change. Higher scores indicate greater perceived improvement

  15. Global Perceived Effect

    Time frame: 6 weeks, 3 months, and 6 months

    Participants' perceived overall effect of treatment will be assessed using the Global Perceived Effect (GPE) scale. The scale ranges from 1 to 7, with higher scores indicating a greater perceived positive effect of treatment.

  16. Patient Acceptable Symptom State

    Time frame: 6 weeks, 3 months, and 6 months

    Patient Acceptable Symptom State (PASS) will be assessed using a single patient-reported item indicating whether participants consider their current symptom state acceptable.

  17. Treatment Failure

    Time frame: 6 weeks, 3 months, and 6 months

    Treatment failure will be assessed using a single patient-reported item indicating whether participants consider their treatment unsuccessful.

  18. Current stress level

    Time frame: Baseline, 6 weeks, 3 months, and 6 months

    Current perceived stress will be assessed using an 11-point numerical rating scale (NRS), with higher scores indicating greater perceived stress.

  19. Register-based healthcare utilisation, medication use, and work participation

    Time frame: From 1 year before inclusion to 1 year after inclusion

    Register-based data will be collected on healthcare utilisation, medication use, and work participation to describe healthcare and societal resource use and to inform the design of a health-economic evaluation in a future definitive RCT. If possible with actual sample size

  20. Adverse Events

    Time frame: From randomisation to 6 months

    Adverse events (AEs) will be monitored throughout the study through participant self-report and therapist reporting during the intervention period. Transient symptom fluctuations or short-term pain associated with physical activity, exercise, or gradual return to usual activities will not in themselves be classified as AEs. Such events will be recorded as AEs if they are unexpected, result in substantial additional burden to the participant, or lead to healthcare contact.

  21. Serious Adverse Events

    Time frame: From randomisation to 6 months

    Serious adverse events (SAEs) will be monitored throughout the study through participant self-report and therapist reporting during the intervention period. SAEs will include events resulting in hospitalisation, significant disability, risk of permanent harm, or another serious medical condition. SAEs will be recorded and reported in accordance with applicable regulatory and ethical requirements.

Study contacts

Contact information is provided by the study sponsor or research team.

René B Jørgensen, Msc

CONTACT

[email protected]

+45 21768003

Sponsors and collaborators

Lead sponsor

University of Southern Denmark

Other

Collaborators

  • Hospital of Southern Jutland
  • Slagelse Hospital
  • Specialized Hospital for Polio and Accident Victims, Rødovre, Denmark
  • Spine Centre of Southern Denmark
  • The Research and Implementation Unit PROgrez, Region Zealand,Denmark
  • University College South Denmark

Registry information

Official study title

Early Stratified Physiotherapy Combined With Stress Inoculation Training for Individuals at Risk of Persistent Post-Traumatic Neck Pain: A Randomized Pilot Trial.

Acronym: StressModex

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Sep 17, 2026
Registry last updated
Sep 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.